Get the latest Science News and Discoveries
Obinutuzumab plus bendamustine as first-line therapy for indolent B-cell lymphomas: a prospective multicenter open-label study
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
None
Or read this on Eureka Alert